ViewRay, Inc. (VRAY)
(Delayed Data from NSDQ)
$7.96 USD
+1.19 (17.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.96 USD
+1.19 (17.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
ViewRay (VRAY) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -6.67% and 0.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 4.82% and 1.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will RxSight, Inc. (RXST) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
RxSight, Inc. (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate ViewRay (VRAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 6.25% and 0.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 2.33% and 0.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay (VRAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 4.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 13.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to gain momentum from a solid product portfolio and a strong General Surgery business. However, data security issues linger.
What Makes ViewRay (VRAY) a New Buy Stock
by Zacks Equity Research
ViewRay (VRAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ViewRay (VRAY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 12.50% and 13.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -6.67% and 2.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Q4 Earnings Lag Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of -47.37% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 38% Upside in ViewRay (VRAY): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 38.4% upside potential for ViewRay (VRAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 6.25% and 15.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment
by Zacks Equity Research
Accuray's (ARAY) latest agreement is likely to improve breast cancer treatment.
ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -18.75% and 6.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay (VRAY) Stock Jumps 11.7%: Will It Continue to Soar?
by Zacks Equity Research
ViewRay (VRAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.
Strength Seen in ViewRay (VRAY): Can Its 13.8% Jump Turn into More Strength?
by Zacks Equity Research
ViewRay (VRAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.